$TGTX
TG THERAPEUTICS, INC.

2020 Form 10-K Financial Statement

#000155837021002149 Filed on March 01, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $152.0K $40.00K $152.0K
YoY Change 0.0% 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $107.9M $7.060M $15.03M
YoY Change 617.71% 269.63% -0.88%
% of Gross Profit
Research & Development $165.9M $30.94M $154.2M
YoY Change 7.6% -40.82% -3.27%
% of Gross Profit
Depreciation & Amortization $158.0K $30.00K $100.0K
YoY Change 58.0% 0.0% 13.64%
% of Gross Profit
Operating Expenses $273.7M $38.00M $169.2M
YoY Change 61.78% -29.88% -3.06%
Operating Profit -$273.6M -$169.1M
YoY Change 61.84% -3.06%
Interest Expense $6.329M -$1.900M $5.287M
YoY Change 19.71% -803.7% 502.85%
% of Operating Profit
Other Income/Expense, Net -$5.787M $290.0K -$3.816M
YoY Change 51.65% 1350.0% -515.69%
Pretax Income -$279.4M -$39.57M -$172.9K
YoY Change 161512.42% -26.53% -0.35%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$279.4M -$39.57M -$172.9M
YoY Change 61.61% -26.53% -0.35%
Net Earnings / Revenue -183803.29% -98927.5% -113730.92%
Basic Earnings Per Share -$2.42
Diluted Earnings Per Share -$2.422M -$413.3K -$1.956M
COMMON SHARES
Basic Shares Outstanding 115.3M 99.56M shares
Diluted Shares Outstanding 115.3M

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $605.4M $140.4M $140.4M
YoY Change 331.2% 104.07% 104.07%
Cash & Equivalents $153.6M $112.6M $2.500M
Short-Term Investments $52.00M $27.80M $27.80M
Other Short-Term Assets $6.300M $611.0K $8.700M
YoY Change -27.59% 39.18% -13.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $611.7M $149.2M $149.2M
YoY Change 309.99% 88.72% 88.86%
LONG-TERM ASSETS
Property, Plant & Equipment $11.80M $282.0K $11.80M
YoY Change 0.0% 12.35% 372.0%
Goodwill $799.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $1.300M $1.300M
YoY Change 0.0% 8.33% 8.33%
Total Long-Term Assets $13.90M $13.86M $13.80M
YoY Change 0.72% 202.36% 200.0%
TOTAL ASSETS
Total Short-Term Assets $611.7M $149.2M $149.2M
Total Long-Term Assets $13.90M $13.86M $13.80M
Total Assets $625.6M $163.0M $163.0M
YoY Change 283.8% 94.96% 94.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $37.00M $30.00M $30.00M
YoY Change 23.33% -17.58% -17.58%
Accrued Expenses $10.10M $5.400M $5.400M
YoY Change 87.04% 134.78% 134.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $23.10M $0.00 $200.0K
YoY Change 11450.0% -100.0% 100.0%
Total Short-Term Liabilities $87.60M $84.45M $84.40M
YoY Change 3.79% 117.35% 116.97%
LONG-TERM LIABILITIES
Long-Term Debt $7.700M $28.97M $29.00M
YoY Change -73.45%
Other Long-Term Liabilities $11.00M $0.00 $11.00M
YoY Change 0.0% -100.0% -46.86%
Total Long-Term Liabilities $18.70M $28.97M $40.00M
YoY Change -53.25% 57.87% 93.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $87.60M $84.45M $84.40M
Total Long-Term Liabilities $18.70M $28.97M $40.00M
Total Liabilities $106.3M $124.4M $124.4M
YoY Change -14.55% 108.79% 108.72%
SHAREHOLDERS EQUITY
Retained Earnings -$701.2M
YoY Change 32.72%
Common Stock $109.0K
YoY Change 29.76%
Preferred Stock
YoY Change
Treasury Stock (at cost) $234.0K
YoY Change 0.0%
Treasury Stock Shares $41.31K
Shareholders Equity $519.4M $38.60M $38.60M
YoY Change
Total Liabilities & Shareholders Equity $625.6M $163.0M $163.0M
YoY Change 283.8% 94.96% 94.98%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$279.4M -$39.57M -$172.9M
YoY Change 61.61% -26.53% -0.35%
Depreciation, Depletion And Amortization $158.0K $30.00K $100.0K
YoY Change 58.0% 0.0% 13.64%
Cash From Operating Activities -$214.5M -$30.40M -$132.8M
YoY Change 61.52% -9.77% 3.01%
INVESTING ACTIVITIES
Capital Expenditures $357.0K -$30.00K $131.0K
YoY Change 172.52% 200.0% 45.56%
Acquisitions
YoY Change
Other Investing Activities -$24.15M $40.00K -$590.0K
YoY Change 3993.22% -83.33% -146.46%
Cash From Investing Activities -$24.51M $0.00 -$718.0K
YoY Change 3313.65% -100.0% -160.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $50.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 679.8M 98.35M 204.2M
YoY Change 232.9% 1997.01% 79.7%
NET CHANGE
Cash From Operating Activities -214.5M -30.40M -132.8M
Cash From Investing Activities -24.51M 0.000 -718.0K
Cash From Financing Activities 679.8M 98.35M 204.2M
Net Change In Cash 440.8M 67.95M 70.69M
YoY Change 523.59% -336.27% -601.13%
FREE CASH FLOW
Cash From Operating Activities -$214.5M -$30.40M -$132.8M
Capital Expenditures $357.0K -$30.00K $131.0K
Free Cash Flow -$214.9M -$30.37M -$132.9M
YoY Change 61.63% -9.83% 3.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6528932
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001001316
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0.001
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0.001
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
1-32639
CY2020 dei Entity Registrant Name
EntityRegistrantName
TG THERAPEUTICS, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort St.
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
9th Floor
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
CY2020 dei City Area Code
CityAreaCode
212
CY2020 dei Local Phone Number
LocalPhoneNumber
554-4484
CY2020 dei Security12b Title
Security12bTitle
Common Stock
CY2020 dei Trading Symbol
TradingSymbol
TGTX
CY2019 tgtx Accrued Financing Costs
AccruedFinancingCosts
988000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2020 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 tgtx Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
2163126348
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
140586187
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553439000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112637000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
51987000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
27798000
CY2020Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
5231000
CY2019Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
8105000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1083000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
611000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
611740000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
149151000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1259000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1251000
CY2020Q4 tgtx Leasehold Interest
LeaseholdInterest
2051000
CY2019Q4 tgtx Leasehold Interest
LeaseholdInterest
2129000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
481000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
282000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9312000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9402000
CY2020Q4 us-gaap Goodwill
Goodwill
799000
CY2019Q4 us-gaap Goodwill
Goodwill
799000
CY2020Q4 us-gaap Assets
Assets
625642000
CY2019Q4 us-gaap Assets
Assets
163014000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
37014000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
30041000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
18236000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48994000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
22179000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1669000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1616000
CY2020Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
8456000
CY2019Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
3798000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
87554000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
84449000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
610000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
762000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7716000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10218000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12081000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28970000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10412000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10218000
CY2020Q4 us-gaap Liabilities
Liabilities
106292000
CY2019Q4 us-gaap Liabilities
Liabilities
124399000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
141000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
140617606
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109425243
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
140576297
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109383934
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
109000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1500040000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
739956000
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-980597000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-701216000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
519350000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38615000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
625642000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
163014000
CY2020 us-gaap Revenues
Revenues
152000
CY2019 us-gaap Revenues
Revenues
152000
CY2018 us-gaap Revenues
Revenues
152000
CY2020 tgtx Non Cash Stock Expense Associated With In Licensing Agreements
NonCashStockExpenseAssociatedWithInLicensingAgreements
0
CY2019 tgtx Non Cash Stock Expense Associated With In Licensing Agreements
NonCashStockExpenseAssociatedWithInLicensingAgreements
100000
CY2018 tgtx Non Cash Stock Expense Associated With In Licensing Agreements
NonCashStockExpenseAssociatedWithInLicensingAgreements
4000000
CY2020 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
13962000
CY2019 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
5811000
CY2018 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
5598000
CY2020 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
151934000
CY2019 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
148269000
CY2018 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
149793000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
165896000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
154180000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159391000
CY2020 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
66327000
CY2019 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
5523000
CY2018 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
7288000
CY2020 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
41523000
CY2019 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
9504000
CY2018 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
7873000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
107850000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15027000
CY2020 us-gaap Interest Expense
InterestExpense
6329000
CY2019 us-gaap Interest Expense
InterestExpense
5287000
CY2018 us-gaap Interest Expense
InterestExpense
877000
CY2020 us-gaap Other Income
OtherIncome
542000
CY2019 us-gaap Other Income
OtherIncome
1471000
CY2018 us-gaap Other Income
OtherIncome
1795000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5787000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3816000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15161000
CY2020 us-gaap Operating Expenses
OperatingExpenses
273746000
CY2019 us-gaap Operating Expenses
OperatingExpenses
169207000
CY2018 us-gaap Operating Expenses
OperatingExpenses
174552000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-273594000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-169055000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-174400000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
918000
CY2020 us-gaap Profit Loss
ProfitLoss
-279381000
CY2019 us-gaap Profit Loss
ProfitLoss
-172871000
CY2018 us-gaap Profit Loss
ProfitLoss
-173482000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.42
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.30
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
115333693
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
88368844
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75466813
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
66993000
CY2018Q4 tgtx Offering Costs
OfferingCosts
2000000.0
CY2018 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
113639000
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
12886000
CY2018 tgtx Stock Issued During Period Value In Licensing Agreements
StockIssuedDuringPeriodValueInLicensingAgreements
4000000
CY2018 us-gaap Profit Loss
ProfitLoss
-173482000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24036000
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
993000
CY2019Q4 tgtx Offering Costs
OfferingCosts
200000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
77475000
CY2019Q4 tgtx Offering Costs At Market
OfferingCostsAtMarket
2000000.0
CY2019 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
97547000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11335000
CY2019 tgtx Stock Issued During Period Value In Licensing Agreements
StockIssuedDuringPeriodValueInLicensingAgreements
100000
CY2019 us-gaap Profit Loss
ProfitLoss
-172871000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38615000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
146000
CY2020Q4 tgtx Offering Costs
OfferingCosts
29900000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
462229000
CY2020Q4 tgtx Offering Costs At Market
OfferingCostsAtMarket
4000000.0
CY2020 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
217452000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
80289000
CY2020 us-gaap Profit Loss
ProfitLoss
-279381000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
519350000
CY2020 us-gaap Profit Loss
ProfitLoss
-279381000
CY2019 us-gaap Profit Loss
ProfitLoss
-172871000
CY2018 us-gaap Profit Loss
ProfitLoss
-173482000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
80289000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
11335000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
12886000
CY2020 tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
0
CY2019 tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
100000
CY2018 tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
4000000
CY2020 us-gaap Depreciation
Depreciation
158000
CY2019 us-gaap Depreciation
Depreciation
100000
CY2018 us-gaap Depreciation
Depreciation
88000
CY2020 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
30000
CY2019 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
257000
CY2018 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
119000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
925000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
772000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2020 us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
216000
CY2019 us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
182000
CY2018 us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
135000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2325000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2519000
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-748000
CY2019 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-124000
CY2018 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
61000
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2263000
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1395000
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1638000
CY2020 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
6000
CY2019 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
11000
CY2018 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-14000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
11631000
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4795000
CY2018 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
10957000
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1988000
CY2019 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1548000
CY2018 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
0
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-43000
CY2019 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1491000
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0
CY2020 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-31462000
CY2019 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
28810000
CY2018 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
18350000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-214507000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-132806000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-128925000
CY2020 tgtx Proceeds From Maturities
ProceedsFromMaturities
43250000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-718000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1180000
CY2020 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
679680000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1259000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
1251000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
1241000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
554698000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113888000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43199000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
4501000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2622000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020 tgtx Accrued Financing Costs
AccruedFinancingCosts
0
CY2019 tgtx Proceeds From Maturities
ProceedsFromMaturities
29250000
CY2018 tgtx Proceeds From Maturities
ProceedsFromMaturities
32500000
CY2020 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
67403000
CY2019 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
29837000
CY2018 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
31230000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
357000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
131000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
90000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24510000
CY2019 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
175021000
CY2018 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
113639000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
147000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2020 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
0
CY2019 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
29987000
CY2018 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
0
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2019 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
795000
CY2018 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
679827000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
204213000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
113639000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
440810000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70689000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14106000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113888000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43199000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57305000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
554698000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113888000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43199000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553439000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112637000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41958000
CY2018 tgtx Accrued Financing Costs
AccruedFinancingCosts
0
CY2020 tgtx Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
0
CY2019 tgtx Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
993000
CY2018 tgtx Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
0
CY2020 tgtx Shares Issued In Connection With In Licensing Agreements Value
SharesIssuedInConnectionWithInLicensingAgreementsValue
0
CY2019 tgtx Shares Issued In Connection With In Licensing Agreements Value
SharesIssuedInConnectionWithInLicensingAgreementsValue
100000
CY2018 tgtx Shares Issued In Connection With In Licensing Agreements Value
SharesIssuedInConnectionWithInLicensingAgreementsValue
4000000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-980600000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
605400000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">USE OF ESTIMATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued clinical trial expenses and stock-based compensation. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p>
CY2019Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1300000
CY2020Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1300000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8361739
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6528932
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">CREDIT RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents and short-term investments with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</p>
CY2020Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
5200000
CY2019Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
8100000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11976276
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8361739
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11976276
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q4 us-gaap Cash
Cash
399879000
CY2019Q4 us-gaap Cash
Cash
110135000
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
153560000
CY2019Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2502000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553439000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112637000
CY2020Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
51987000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
1000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
4000
CY2020Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
51984000
CY2019Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
27798000
CY2019Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
28000
CY2019Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
27826000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
938000
CY2020Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
938000
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
190000
CY2019Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
190000
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
67000
CY2019 tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
924000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-801000
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
190000
CY2020 tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
976000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-228000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
938000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
100.00
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2014Q3 tgtx Number Of Days Rights Become Exercisable
NumberOfDaysRightsBecomeExercisable
P10D
CY2014Q3 tgtx Common Stock Years Before Rights Will Expire
CommonStockYearsBeforeRightsWillExpire
P10Y
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 tgtx Common Stock Commission Rate
CommonStockCommissionRate
0.030
CY2019Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5434783
CY2019Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.20
CY2019Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
50000000.0
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1866250
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
147058
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
938000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2020Q4 us-gaap Notes Payable
NotesPayable
938000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
190000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2019Q4 us-gaap Notes Payable
NotesPayable
190000
CY2020 tgtx Cumulative Liability Of Note
CumulativeLiabilityOfNote
20300000
CY2019 tgtx Cumulative Liability Of Note
CumulativeLiabilityOfNote
19300000
CY2020 tgtx Agreement Costs Aggregate
AgreementCostsAggregate
53700000
CY2020Q4 us-gaap Construction Contract Cost Progress Payment Offset
ConstructionContractCostProgressPaymentOffset
37400000
CY2020 tgtx Agreement Costs Current Liabilities
AgreementCostsCurrentLiabilities
15700000
CY2019 tgtx Agreement Costs Current Liabilities
AgreementCostsCurrentLiabilities
47200000
CY2020 tgtx Agreement Costs Current Liabilities
AgreementCostsCurrentLiabilities
15700000
CY2020 tgtx Percentage Of Administrative Fee
PercentageOfAdministrativeFee
0.06
CY2020 tgtx Interest Expense Recognized As Administrative Fees
InterestExpenseRecognizedAsAdministrativeFees
1200000
CY2019 tgtx Interest Expense Recognized As Administrative Fees
InterestExpenseRecognizedAsAdministrativeFees
1200000
CY2018 tgtx Interest Expense Recognized As Administrative Fees
InterestExpenseRecognizedAsAdministrativeFees
0
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11834000
CY2020Q4 tgtx End Of Term Fee
EndOfTermFee
975000
CY2019Q4 tgtx End Of Term Fee
EndOfTermFee
975000
CY2020Q4 tgtx Long Term Debt Gross
LongTermDebtGross
30975000
CY2019Q4 tgtx Long Term Debt Gross
LongTermDebtGross
30975000
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1080000
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2005000
CY2020Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
30000000
CY2019Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
30000000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
29895000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
28970000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
22179000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7716000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28970000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
2656000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
2651000
CY2018 us-gaap Operating Lease Cost
OperatingLeaseCost
1440000
CY2020 us-gaap Lease Cost
LeaseCost
2656000
CY2019 us-gaap Lease Cost
LeaseCost
2651000
CY2018 us-gaap Lease Cost
LeaseCost
1440000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1669000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1616000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12081000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-279381000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2012000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2035000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2040000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1923000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1653000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
9884000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19547000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7466000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
276700000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
186700000
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
956300000
CY2020Q4 tgtx Research And Development Carryforward
ResearchAndDevelopmentCarryforward
27600000
CY2020Q4 tgtx Business Interest Expense Carryforward
BusinessInterestExpenseCarryforward
7500000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
223685000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
158177000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
27558000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
22483000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
22381000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
4680000
CY2020Q4 tgtx Deferred Tax Asset Disallowed Interest
DeferredTaxAssetDisallowedInterest
1855000
CY2019Q4 tgtx Deferred Tax Asset Disallowed Interest
DeferredTaxAssetDisallowedInterest
710000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1224000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
661000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
276703000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
186711000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
276703000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
186711000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-172871000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1292000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-473
CY2020 tgtx Effects Of Federal Tax Reform Rate Changes
EffectsOfFederalTaxReformRateChanges
-14763000
CY2019 tgtx Effects Of Federal Tax Reform Rate Changes
EffectsOfFederalTaxReformRateChanges
0
CY2018 tgtx Effects Of Federal Tax Reform Rate Changes
EffectsOfFederalTaxReformRateChanges
0
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-173482
CY2020 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-58670000
CY2019 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-36303000
CY2018 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-36431
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-10801000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2128000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2243
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
5265000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
7266000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4726
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1065000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
641000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
639
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-1558000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
89992000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
43764000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
43234
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Contractual Obligation
ContractualObligation
65200000
CY2020Q4 us-gaap Contractual Obligation
ContractualObligation
65217000
CY2020Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
39860000
CY2020Q4 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
11896000
CY2020Q4 us-gaap Contractual Obligation Due In Fourth And Fifth Year
ContractualObligationDueInFourthAndFifthYear
3577000
CY2020Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
9884000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000

Files In Submission

Name View Source Status
0001558370-21-002149-index-headers.html Edgar Link pending
0001558370-21-002149-index.html Edgar Link pending
0001558370-21-002149.txt Edgar Link pending
0001558370-21-002149-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgtx-20201231.xsd Edgar Link pending
tgtx-20201231x10k.htm Edgar Link pending
tgtx-20201231x10k001.jpg Edgar Link pending
tgtx-20201231x10k_htm.xml Edgar Link completed
tgtx-20201231xex21d1.htm Edgar Link pending
tgtx-20201231xex23d1.htm Edgar Link pending
tgtx-20201231xex31d1.htm Edgar Link pending
tgtx-20201231xex31d2.htm Edgar Link pending
tgtx-20201231xex32d1.htm Edgar Link pending
tgtx-20201231xex32d2.htm Edgar Link pending
tgtx-20201231xex4d5.htm Edgar Link pending
tgtx-20201231_cal.xml Edgar Link unprocessable
tgtx-20201231_def.xml Edgar Link unprocessable
tgtx-20201231_lab.xml Edgar Link unprocessable
tgtx-20201231_pre.xml Edgar Link unprocessable